I WOULD LIKE TO

Cancer Clinical Trials

Clinical trials are research studies for cancer treatments that are still in the development phase.

The Mon Health Cancer Center is committed to participation in clinical trials for our patients on a case-by-case basis. As an affiliate member of NRG Oncology, we have the ability to offer clinical trials associated with the leading oncology research centers and national cooperative groups.

It’s important to note that, for many reasons, not all patients will be eligible for a clinical trial. There are very strict patient eligibility requirements that are specific to each clinical trial.  We look forward to the opportunity to discuss this possible option with you.

Clinical trials are done in phases. Each phase has a different purpose, the National Institute of Health says:

  • Phase I trials use a small group of people, usually 20-80, to check the safety, dosage and side effects of a treatment.
  • Phase II trials expand to 100-300 people and look at the effectiveness and safety of a treatment.
  • Phase III trials include 1,000-3,000 people and try to confirm the results of the earlier trials and compare the new treatment with other commonly used treatments.

  • Mon Health Medical Center primarily focuses on Phase II and Phase III trials. If interested, please speak to your doctor or call our Clinical Trial Coordinator at 304-598-6581.

    Open Clinical Trials for Hematology Oncology

    S1207:  Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of Everolimus in patients with high-risk hormone receptor-positive AND HER2/neu negative breast cancer.  READ MORE…

    ECOG-EAY131: Match Study - A Phase II precision medicine trial that seeks to determine whether matching certain drugs or drug combinations in adults whose tumors have specific gene abnormalities will effectively treat their cancer, regardless of their cancer type.

    Open Clinical Trials for Gynecologic Oncology

    GOG-0225:  Can diet and physical activity modulate ovarian, fallopian tube and primary peritoneal cancer progression-free survival? 

    READ MORE…

    GOG-0278:  Evaluation of physical function and quality of life (QOL) before and after non-radical surgical therapy (extra fascial hysterectomy or cone biopsy with pelvic lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB1 (≤ 2CM) cervical cancer. 

    READ MORE…

    ProMark:  A Collaborative Study with The University of Pittsburgh Medical Centers. Prognostic Marker: Acquisition of Blood Samples and Tissue for Research Purposes.  READ MORE… 

    ECOG-EAY131: Match Study - A Phase II precision medicine trial that seeks to determine whether matching certain drugs or drug combinations in adults whose tumors have specific gene abnormalities will effectively treat their cancer, regardless of their cancer type.

    PR-30-5017-C: A study of Niraparib Maintenance treatment in patients with HRD-positive advanced ovarian cancer following response on front-line platinum-based chemotherapy.

    NRG-GY003: A Phase II randomized trial of Nivolumab with or without Ipilimumab in patients with persistent or recurrent epithelial ovarian, primary peritoneal or fallopian tube cancer.

    NRG-GY004: A Phase III study comparing single-agent Olaparib or the combination of Cediranib and Olaparib to standard ovarian, fallopian tube or primary peritoneal cancer.

    NRG-GY005: A Randomized Phase II/III study of the combination of Cebiranib and Olaparib compared to Cediranib or Olaparib alone, of standard of care chemotherapy in women with recurrent platinum-resistant or refractory ovarian, fallopian tube or primary peritoneal cancer (COCOS).

    If you would like to learn more about clinical trials, here are some useful links:

    ClinicalTrials.gov—a worldwide clinical studies database from the US National Institutes of Health 
    Cancer.gov—a cancer-specific resource on clinical trials from the National Cancer Institute at the National Institutes of Health
    NRG Oncology – a resource for the clinical trials by the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG) and the Gynecologic Oncology Group (GOG)  
    Back to Top
    Contact the Mon Health Cancer Center
    1200 JD Anderson Drive
    Morgantown, WV 26505

    Patient Information:
    304-598-6560
    General Information:
    304-598-6578
    Medical Oncology:
    304-598-6560
    Gynecologic Oncology:
    304-285-3870
    Infusion Center: 
    304-285-2902
    Radiation Oncology
    304-285-2220

    Send us a message
    Joint Commission Healthgrades Achievements Chest Pain Center BDC Commission on Cancer Benefits Summary